| Comprehensive genomic characterization of squamous cell lung cancers Cancer Genome Atlas Research Network Nature 489 (7417), 519, 2012 | 3718 | 2012 |
| Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ... New England Journal of Medicine 374 (4), 311-322, 2016 | 2074 | 2016 |
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1962 | 2014 |
| Evolution and impact of subclonal mutations in chronic lymphocytic leukemia DA Landau, SL Carter, P Stojanov, A McKenna, K Stevenson, ... Cell 152 (4), 714-726, 2013 | 1641 | 2013 |
| SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia L Wang, MS Lawrence, Y Wan, P Stojanov, C Sougnez, K Stevenson, ... New England Journal of Medicine 365 (26), 2497-2506, 2011 | 1399 | 2011 |
| Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ... New England Journal of Medicine 374 (4), 323-332, 2016 | 1035 | 2016 |
| Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 986 | 2018 |
| Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease AW Roberts, JF Seymour, JR Brown, WG Wierda, TJ Kipps, SL Khaw, ... Journal of Clinical Oncology 30 (5), 488-496, 2012 | 945 | 2012 |
| Targeting transcription regulation in cancer with a covalent CDK7 inhibitor N Kwiatkowski, T Zhang, PB Rahl, BJ Abraham, J Reddy, SB Ficarro, ... Nature 511 (7511), 616-620, 2014 | 859 | 2014 |
| Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 VDG Moore, JR Brown, M Certo, TM Love, CD Novina, A Letai The Journal of clinical investigation 117 (1), 112-121, 2007 | 752 | 2007 |
| Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia JR Brown, JC Byrd, SE Coutre, DM Benson, IW Flinn, ... Blood, The Journal of the American Society of Hematology 123 (22), 3390-3397, 2014 | 741 | 2014 |
| Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ... American journal of hematology 94 (12), 1353-1363, 2019 | 456 | 2019 |
| MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele … L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao, X Liu, E Morra, A Trojani, ... Blood, The Journal of the American Society of Hematology 121 (11), 2051-2058, 2013 | 450 | 2013 |
| A defect in nurturing in mice lacking the immediate early gene fosB JR Brown, H Ye, RT Bronson, P Dikkes, ME Greenberg Cell 86 (2), 297-309, 1996 | 443 | 1996 |
| Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia A Yoda, Y Yoda, S Chiaretti, M Bar-Natan, K Mani, SJ Rodig, N West, ... Proceedings of the National Academy of Sciences 107 (1), 252-257, 2010 | 413 | 2010 |
| Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia LZ Rassenti, S Jain, MJ Keating, WG Wierda, MR Grever, JC Byrd, ... Blood, The Journal of the American Society of Hematology 112 (5), 1923-1930, 2008 | 407 | 2008 |
| Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study S O'Brien, JA Jones, SE Coutre, AR Mato, P Hillmen, C Tam, A Österborg, ... The Lancet Oncology 17 (10), 1409-1418, 2016 | 401 | 2016 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 391 | 2021 |
| Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition JA Burger, DA Landau, A Taylor-Weiner, I Bozic, H Zhang, K Sarosiek, ... Nature communications 7 (1), 11589, 2016 | 387 | 2016 |
| Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia DA Landau, K Clement, MJ Ziller, P Boyle, J Fan, H Gu, K Stevenson, ... Cancer cell 26 (6), 813-825, 2014 | 386 | 2014 |
